Congenital adrenal hyperplasia treatment took a significant step forward at ENDO 2026, where Crinetics’ atumelnant — an oral ...
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to ...
Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol ...
Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics ...
At the recent American Association of Clinical Endocrinology annual meeting, experts shared updates on the complexities of diagnosing and managing Cushing's disease, including novel drug strategies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results